Printer Friendly

WCG acquires Analgesic Solutions.

Byline: Anthony Vecchione

Princeton-based WIRB-Copernicus Group WCG Clinical Services Division announced the acquisition of Analgesic Solutions LLC, a developer of pain medications and supporter of clinical trials in which pain is an indicator of an underlying condition.

Analgesic Solutions joins the family of WCG clinical services that facilitate and optimize the conduct of clinical trials. WCG's newest addition focuses on increasing assay sensitivity in clinical trials through consulting, innovative tools, data science, technology and specialized training.

"We are delighted to welcome Dr. Nathaniel Katz, the founder and chief scientist of Analgesic Solutions, and his extraordinary team of clinicians and scientists to WCG," said Donald Deieso, executive chairman and chief executive officer of WCG, in a statement. "The intense public focus on developing alternatives to opioids for use in pain management, as well the organization's deep understanding of patients' subjective responses to pain, has made Analgesic Solutions one of the most sought-after solution providers in clinical research," Deieso said.

"We are very pleased to join WCG an organization which shares our values, our purpose, and above all, our commitment to scientific integrity," said Katz, founder and chief science officer, Analgesic Solutions. "What excites us most about collaborating with our colleagues at WCG is helping biopharmaceutical sponsors to accelerate the development of pain-reducing therapies by improving the quality of clinical research in this area," he said.

Dr. Jeffrey Litwin, chiefoperating officer of WCG, said that together with WCG's MedAvante-ProPhase service line, Analgesic Solutions encompasses a comprehensive view of the subjective responses of patients in clinical trials. "Our protocol design expertise and proven methods for decreasing subjectivity help sponsors avoid creating conditions in which a good drug might fail, or in which patients might be treated longer than necessary with a drug that simply doesn't work. Our clients save time and money by determining more quickly and clearly whether a drug is effective or not."

Robert Newman, CEO of Analgesic Solutions, said that the quest to combat the misuse and abuse of pharmaceuticals and to uncover effective pain management alternatives has brought many new players to the space. "What they are finding is that these types of trials have their own unique challenges and are, in fact, quite difficult to conduct. We are proud to support newcomers, as well as our old friends, with the clinical and scientific expertise they need to conduct successful trials and offer renewed hope to those suffering from chronic pain and other debilitating diseases around the world," Newman said.

Analgesic Solutions will continue to operate independently and retain its headquarters in Wayland, Mass. WCG will provide Analgesic Solutions with access to capital, expertise and corporate operational support.

Copyright {c} 2019 BridgeTower Media. All Rights Reserved.

COPYRIGHT 2019 BridgeTower Media Holding Company, LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2019 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Author:Vecchione, Anthony
Publication:NJ Biz
Date:Apr 4, 2019
Words:447
Previous Article:Lakeland Bank announces 2019 employee promotions.
Next Article:HFF announces $8.5M sale of new industrial warehouse in Hamilton.
Topics:

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |